Side-by-side research comparison of Dulaglutide and Tirzepatide across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 42 Dulaglutide studies and 722 Tirzepatide studies.
| Dulaglutide | Tirzepatide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist, gip agonist |
| Studies in corpus | 42 | 722 |
| Highest evidence tier | meta analysis | — |
| Evidence tier mix | cohort · 1 rct · 15 review · 3 meta analysis · 6 other · 7 | n/a |
| Studies with explicit sample size | 6 | 0 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Dulaglutide and Tirzepatide batches we've tested. Aggregate, public data — cross-reference against the studies below.
Fewer than 3 published Dulaglutide COA records so far — not enough for a meaningful purity aggregate yet. Browse what we have →
We tested 10730 Tirzepatide batches across 1651 manufacturers, 99.72% avg purity.
Looking for vendor-level purity, endotoxin, and HPLC data on Dulaglutide or Tirzepatide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.